This is the second competing renewal application of the Vanderbilt-lngram Cancer Center (VICC) Breast Cancer SPORE Grant. We have made significant progress in our previous funding cycle, have established productive collaborations with other Breast Cancer SPOREs and national and international groups, and have firmly established a true multidisciplinary program which we believe will be increasingly productive in the years to come. Our overall goal continues to be to conduct multidisciplinary, mechanism-based, translational research of the highest possible impact that will contribute meaningfully to measurable progress in breast cancer. To this end and after internal and external review, we now propose four bidirectional translational projects addressing basic, clinical and population research questions in human breast cancer. Two of these are continuations and two are new projects. The application also includes five shared cores resources, and developmental research and career development programs. Project 1: Inhibition of PI3 kinase as a strategy to abrogate antiestrogen resistance in breast cancer Project 2: Strategies to improve outcomes for triple negative breast cancer patients involving subtype-specific targeted therapies and genomic discovery Project 3: Mcl-1 inhibitors for the treatment of breast cancer Project 4: The obesity-metabolic biomarker axis and breast cancer risk Core Resources. To support the research aims in the translational research projects, we propose five shared Core Resources. Each of these Cores supports at least 2 projects in this competing renewal. They are Administration &Outreach, Pathology &Tissue Informatics (formerly called Tissue), Clinical, Biostatistics, and Imaging Cores. We should emphasize that these Cores do not duplicate pre-existing resources available at VICC or VUMC. The proposed Projects will require additional personnel and funded effort over that already maximally utilized in equivalent institutional Core Resources.
These four projects will transform how we diagnose and treat individuals with breast cancer and deepen our understanding of the pathobiology of mammary neoplasia. A patient advocate is an integral member of each project to help ensure that our translational goals are being met.
|Bhola, Neil E; Jansen, Valerie M; Bafna, Sangeeta et al. (2015) Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Res 75:405-14|
|Sanders, Melinda E; Schuyler, Peggy A; Simpson, Jean F et al. (2015) Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol 28:662-9|
|Abramson, Vandana G; Lehmann, Brian D; Ballinger, Tarah J et al. (2015) Subtyping of triple-negative breast cancer: implications for therapy. Cancer 121:16-Aug|
|Guo, Yan; Zhao, Shilin; Lehmann, Brian D et al. (2014) Detection of internal exon deletion with exon Del. BMC Bioinformatics 15:332|
|Barnes, Stephanie L; Quarles, C Chad; Yankeelov, Thomas E (2014) Modeling the effect of intra-voxel diffusion of contrast agent on the quantitative analysis of dynamic contrast enhanced magnetic resonance imaging. PLoS One 9:e108726|
|Grieb, Brian C; Chen, Xi; Eischen, Christine M (2014) MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival. Mol Cancer Res 12:1216-24|
|Su, Pei-Fang; Li, Chung-I; Shyr, Yu (2014) Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates. Comput Stat Data Anal 74:39-51|
|Bi, Xiaohong; Rexer, Brent; Arteaga, Carlos L et al. (2014) Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy. J Biomed Opt 19:025001|
|Jiang, Junfeng; Jia, Peilin; Shen, Bairong et al. (2014) Top associated SNPs in prostate cancer are significantly enriched in cis-expression quantitative trait loci and at transcription factor binding sites. Oncotarget 5:6168-77|
|Jiang, Junfeng; Jia, Peilin; Zhao, Zhongming et al. (2014) Key regulators in prostate cancer identified by co-expression module analysis. BMC Genomics 15:1015|
Showing the most recent 10 out of 195 publications